The Global Disease Control and Prevention Vaccine Market , by Product Type (Live-Attenuated, Inactivated, Recombinant Sub Unit, and Toxoid), by Type (Monovalent and Multivalent), By Route of Administration (Oral and Injectable), by Age Group (Pediatric Vaccine and Adult Vaccine), By Indication (Infectious Disease, Cancer and Other Indications) was valued US$ 41.12 billion in 2017 and is projected to exhibit a CAGR of 12.1% over the forecast period (2017 - 2025) as highlighted in a new report published by Coherent Market Insights. New product launches by market players coupled with rising government immunization programs are the major factors driving growth of the global disease control and prevention vaccine market over the forecast period.
Request to Sample Report @ https://www.coherentmarketinsights.com/insight/request-sample/1500
Vaccines aid in control and prevention of viral and bacterial disease. Vaccines for infectious disease has large impact on reducing disease incidence and burden of vaccine preventable disease. According to Centers for Disease Control and Prevention (CDC), in 2013, around 226,000 people are hospitalized every year and between 3,000 and 49,000 people die due to influenza and its complications. The global efforts to tackle infectious disease by better surveillance and immunization system enhanced effectiveness of the immunization program. For instance, according to World Health Organization (WHO), incidence of polio are decreased by 99% as of 2018 as compare to 1988, attributed to global initiatives for polio eradication by public and private organizations. Furthermore, increasing government initiative to strengthen immunization program are expected to augment the growth of disease control and prevention vaccine market. For instance, in 2017, Minister of Health from 194 countries endorsed Global Vaccine Action Plan to prevent millions of death through more access to vaccine by 2020. Moreover, manufacturers are focusing on the developing new vaccine with better safety and immunity for the disease at low cost.
Browse 47 Market Data Tables and 45 Figures spread through 210 Pages and in-depth TOC on “Disease Control and Prevention Vaccine Market, by Product Type (Live-Attenuated, Inactivated, Recombinant Sub Unit and Toxoid), by Type (Monovalent and Multivalent), By Route of Administration (Oral and Injectable), by Age Group (Pediatric Vaccine and Adult Vaccine), By Indication (Infectious Disease, Cancer and Other Indications) - Global Forecast to 2025”
Manufactures in vaccine market are focused on research and developmental activities for developing new vaccine with better safety and immunity for the disease at low cost and to strengthen the product portfolio. For instance, in 2017, GlaxoSmithKline plc, received US FDA approval for phase III clinical trial of its product Shingrix, a recombinant sub unit vaccine, for shingles infection in adults. Moreover, manufacturers are targeting disease such as HIV or dengue to expand product portfolio. For instance, in 2018, Sanofi received US FDA approval for its dengue vaccine, Dengvaxia. Furthermore, merger and acquisition are adopted by key players to expand the company share. In 2014, Pfizer Inc., acquired Baxter’s portfolio, which includes of marketed vaccines for US$ 648 million. The portfolio includes NeisVac-C and FSME-IMMUN/TicoVac vaccines against meningitis by group C meningococcal meningitis and tick-borne encephalitis, respectively.
Ask for customization: https://www.coherentmarketinsights.com/insight/request-customization/1500
Key takeaways of the Disease Control and Prevention Vaccine Market:
The global disease control and prevention vaccine market is expected to expand at a CAGR of 12.1% during the forecast period (2017–2025), owing to presence of untapped and highly lucrative market especially in Asia Pacific, Latin America, Middle East, and Africa.
Recombinant vaccine hold major market share due to increasing awareness regarding disease prevention
Monovalent vaccines segment holds largest revenue share among type segment due to high rate of safety and stability of the vaccine
Among age group, pediatric vaccines hold largest market share, owing to increasing government initiative for child vaccination program
Infectious disease segment holds largest market share owing to high prevalence infectious disease such as typhoid, measles, hepatitis etc.
Some of the major players involved in global disease control and prevention vaccine market include GlaxoSmithKline plc (GSK), Merck & Co. Inc., Sanofi, AstraZeneca PLC, Pfizer, Inc., Serum Institute of India Pvt. Ltd., Sinovac Biotech Ltd., Astellas Pharma Inc., and Daiichi Sankyo
